|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2007-11-20
|
|
pubmed:abstractText |
Ibritumomab tiuxetan radioimmunotherapy produces durable remissions in patients with relapsed/refractory indolent non-Hodgkin lymphoma. The dosing of Yttrium 90 (90Y)-ibritumomab tiuxetan is based on patient weight and platelet count: 0.4 mCi/kg in patients with a count >or= 150 x 10(9)/L, to a maximum dose of 32 mCi. Patients weighing > 80 kg with platelet counts of >or= 150 x 10(9)/L receive a lower dose per unit of body weight. We evaluated whether this influences the safety or efficacy of treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1557-9190
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
514-7
|
|
pubmed:meshHeading |
pubmed-meshheading:18021468-Adult,
pubmed-meshheading:18021468-Aged,
pubmed-meshheading:18021468-Aged, 80 and over,
pubmed-meshheading:18021468-Antibodies, Monoclonal,
pubmed-meshheading:18021468-Body Weight,
pubmed-meshheading:18021468-Female,
pubmed-meshheading:18021468-Humans,
pubmed-meshheading:18021468-Lymphoma, B-Cell,
pubmed-meshheading:18021468-Male,
pubmed-meshheading:18021468-Middle Aged,
pubmed-meshheading:18021468-Platelet Count,
pubmed-meshheading:18021468-Radioimmunotherapy,
pubmed-meshheading:18021468-Radiopharmaceuticals,
pubmed-meshheading:18021468-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
|
|
pubmed:affiliation |
Mayo Clinic, Rochester, MN, USA.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Clinical Trial, Phase II,
Clinical Trial, Phase I,
Clinical Trial, Phase III
|
